Zai Lab Limited (HKG:9688)
28.80
+0.30 (1.05%)
Apr 3, 2025, 4:08 PM HKT
Zai Lab Revenue
In the year 2024, Zai Lab had annual revenue of $398.99M USD with 49.59% growth. Zai Lab had revenue of $109.07M in the quarter ending December 31, 2024, with 65.68% growth.
Revenue
$398.99M
Revenue Growth
+49.59%
P/S Ratio
n/a
Revenue / Employee
$213.48K
Employees
1,869
Market Cap
31.14B HKD
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 398.99M | 132.27M | 49.59% |
Dec 31, 2023 | 266.72M | 51.68M | 24.03% |
Dec 31, 2022 | 215.04M | 70.73M | 49.01% |
Dec 31, 2021 | 144.31M | 95.35M | 194.77% |
Dec 31, 2020 | 48.96M | 35.97M | 277.04% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
BeiGene | 29.60B |
Hansoh Pharmaceutical Group Company | 13.05B |
WuXi Biologics | 19.87B |
JD Health International | 61.89B |
Innovent Biologics | 10.03B |
Akeso | 2.26B |
Alibaba Health Information Technology | 31.39B |
Sichuan Kelun-Biotech Biopharmaceutical | 2.06B |
Zai Lab News
- 8 days ago - Zai Lab to Present New Data from Internally Developed, Next-Generation Oncology Candidates at AACR 2025 Annual Meeting - Business Wire
- 13 days ago - Zai Lab: Innovative Pharma Set For Strong Year Of Business (And Share Price) Growth - Seeking Alpha
- 14 days ago - Zai Lab: Still Attractive Despite Higher Costs And Added Trade War Risks - Seeking Alpha
- 21 days ago - Zai Lab gets China review for Pfizer-partnered cervical cancer therapy - Seeking Alpha
- 22 days ago - Zai Lab Announces Acceptance of Biologics License Application for TIVDAK for the Treatment of Patients with Recurrent or Metastatic Cervical Cancer - Business Wire
- 4 weeks ago - Insider Sell: Richard Gaynor Sells 2,500 Shares of Zai Lab Ltd (ZLAB) - GuruFocus
- 4 weeks ago - Zai Lab Announces Participation in Investor Conferences in March 2025 - Business Wire
- 5 weeks ago - Decoding Zai Lab Ltd (ZLAB): A Strategic SWOT Insight - GuruFocus